Marta Gaggiola
YOU?
Author Swipe
View article: Case Report: Asymptomatic macular edema in ozanimod
Case Report: Asymptomatic macular edema in ozanimod Open
We report the case of a 61-year-old patient with relapsing–remitting multiple sclerosis (RRMS) who developed asymptomatic macular edema (ME) after initiation of ozanimod, a sphingosine-1-phosphate receptor (S1PR) modulator. The patient had…
View article: The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis Open
Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests th…
View article: A comparison of natalizumab’s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients
A comparison of natalizumab’s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients Open
Background Pediatric-onset multiple sclerosis (POMS) patients often exhibit a wide range of cognitive deficits. Therefore, therapeutic approaches should aim not only to prevent cognitive decline but also to promote cognitive improvement. O…
View article: High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis
High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis Open
The favorable outcomes observed on clinical, especially in PIRA, and radiologic parameters strongly support the use of NTZ as a first-choice HET in POMS.
View article: Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis
Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis Open
BBB damage in MS is linked to a specific CSF cytokines pattern (CXCL-9, CXCL-10, IL-16), that are also involved in astrocyte-microglia interaction. To what extent their continuous production in the CNS may mark a more severe disease course…
View article: Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis Open
Background: Paediatric-onset multiple sclerosis (POMS) therapeutic approach derives from of adult-onset multiple sclerosis (AOMS) tailored algorithms. Objectives: To evaluate in a common clinical scenario the efficacy and safety of alemtuz…